Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Pyxis Oncology's annualized net income for the quarter that ended in Mar. 2024 was $-13.02 Mil. Pyxis Oncology's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $130.91 Mil. Therefore, Pyxis Oncology's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -9.95%.
The historical rank and industry rank for Pyxis Oncology's Return-on-Tangible-Equity or its related term are showing as below:
PYXS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -61.85 Med: -57.19 Max: -42.82
Current: -42.82
During the past 5 years, Pyxis Oncology's highest Return-on-Tangible-Equity was -42.82%. The lowest was -61.85%. And the median was -57.19%.
PYXS's Return-on-Tangible-Equity is ranked better than 52.11% of 1301
companies
in the Biotechnology industry
Industry Median: -46.42
vs PYXS: -42.82
Pyxis Oncology Return-on-Tangible-Equity Historical Data
The historical data trend for Pyxis Oncology's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pyxis Oncology's Return-on-Tangible-Equity
For the Biotechnology subindustry, Pyxis Oncology's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology's Return-on-Tangible-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Pyxis Oncology Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Pyxis Oncology's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Pyxis Oncology (Pyxis Oncology) Business Description
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PYXS has been successfully added to your 